Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

Podcasts

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

Articles

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.  

FDA Requiring Black Box Warning for Certain JAK Inhibitors  

Videos

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

FDA Delays Impacting Inflammatory Skin Disease Community

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.

Brace for Breakthroughs in Psoriasis, Psoriatic Arthritis

and joined the MJH Life Sciences team in April 2021. She graduated from Kent State University in 2018 with a bachelor's degree in journalism and a minor in sociology. Linda used to work as a creative writer for 

 and was a technical writer/regulatory specialist/purchasing agent at GM Industrial before coming on to the team. She enjoys reading, traveling, and learning new perspectives. You can reach her at 

Amgen and the International Federation of Psoriasis Associations have announced their efforts to combat the challenges of psoriasis.

Amgen and IFPA Launch UPLIFT Innovation Challenge

Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.  

Mental Health Affects Psoriatic Arthritis Treatment

The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.

FDA Fails to Provide Approval Decision on Upadacitinib for PsA 

COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis. 

Guselkumab Demonstrates Efficacy in Phase 3b Study

Ilya Petrou, MD, is a contributing writer for 

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases. 

Dangers, Benefits of Biologics Must Be Carefully Weighed

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.  